[ TRANSACTION RECORD ]

AbbVie Inc. Investment in Cerevel Therapeutics — 2023

VERIFIED VECTOR ID: 001818 · tx-104
M SOURCE NODE — FUNDER
AbbVie Inc.
Healthcare United States
$8,700,000,000
EQUITY
06/12/2023
Q DESTINATION NODE — RECIPIENT
Cerevel Therapeutics
Company United States
Amount (USD)
$8.7B
Flow Type
EQUITY
Transaction Date
06/12/2023
Primary Source
View Filing ↗
Funder Profile [ M ]
Entity AbbVie Inc.
AUM 300000
HQ Location United States
Sector Healthcare
Recipient Profile [ Q ]
Entity Cerevel Therapeutics
Entity Type Company
Jurisdiction United States
Intelligence Note

AbbVie Inc. entered into a definitive agreement to acquire Cerevel Therapeutics for 8.7 billion dollars to expand its neuroscience drug pipeline. The transaction focuses on advanced treatments for Parkinson’s disease and mood disorders. This deal represents a major institutional investment in the advancement of medicine for complex central nervous system conditions.

Σ
Primary Forensic Source https://news.abbvie.com/2023-12-06-AbbVie-to-Acquire-Cerevel-Therapeutics-in-Strategic-Step-to-Strengthen-Neuroscience-Pipeline/
✓ SOURCE LINKED